Fleur Chandler is a health economist with more than thirty years’ experience in market access, evidence generation, and clinical trials. She works with the patient organisation Duchenne UK in advocacy and access, and she is the founder and director of Fleur Chandler Consulting Ltd, advising industry, charities, and policy groups on reimbursement strategy and system reform, with a particular focus on rare paediatric and progressive conditions.

Fleur began her career in GSK research and development, with roles in clinical trials and statistics and market access, at UK and global level, finally serving as global head of value, evidence and outcomes for respiratory and pipeline, leading global evidence strategies, real world data programmes, and value frameworks for late stage and emerging assets. She later joined Sanofi as head of market access UK and Ireland, overseeing national pricing, reimbursement, and health technology assessment (HTA) strategy across multiple therapeutic areas.

She has worked with NICE since its inception, as part of the GSK team for NICE’s first technology appraisal in 2000. Over the years, she has held multiple roles across the UK HTA landscape, including industry representative to the All Waled Medicine Strategy Group and a position on the NICE Operational Effectiveness Group. She contributes to NICE committees both as an industry expert and as a patient representative, bringing methodological insight and lived experience to complex evaluations. Fleur conceptualised and now leads HERCULES with Duchenne UK, an award winning multistakeholder initiative generating evidence for HTA for Duchenne Muscular Dystrophy and other rare paediatric conditions.

Alongside her professional work, Fleur is a parent and carer to her 19 year old son, Dom, who is living with Duchenne. This dual perspective, combining technical expertise with lived experience, informs her commitment to improving how evidence is generated, interpreted, and applied for children and young adults with progressive conditions.